A stability-indicating UPLC method for the determination of curcumin diethyl disuccinate, an ester prodrug of curcumin, in raw materials

Pahweenvaj Ratnatilaka Na Bhuket a, Wisut Wichitnithad a, b, Orawan Sudtanon b, Pornchai Rojsithisak a, c *,

a Natural Products for Ageing and Chronic Diseases Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand
b Department of Analytical Development, Pharma Nueva Co., Ltd., Bangkok, 10900, Thailand
c Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand

Abstract

A stability-indicating reversed-phase ultra-performance liquid chromatographic (UPLC) method for quantitative analysis of curcumin diethyl disuccinate (CDD) in raw materials was developed for applications in product development and quality control. Chromatographic separation was performed using the Waters ACQUITY UPLC® H-Class system consisting of an ACQUITY UPLC® BEH C18 (1.7 μm, 2.1 × 50 mm) column and a photodiode array detector set at a wavelength of 400 nm. The mobile phase consisting of 2%v/v acetic acid in water and acetonitrile was delivered at a flow rate of 0.3 mL/min under gradient elution program. The method was validated according to the ICH Q2(R1) guideline for the validation of analytical procedures. The method was found to be linear over the concentration range of 8 – 12 μg/mL with the coefficient of determination >0.995. The accuracy of the method established as %recovery ranged from 98.3 – 100.8%. The precision of the method expressed as %CV was found to be <1%. The coelution of degradation products from six stress test conditions was not observed. The robustness of the method was not observed. The method was successfully applied in the determination of CDD content in raw materials.

1. Introduction

Curcumin diethyl disuccinate (CDD, Figure 1B) is an ester prodrug of curcumin (Figure 1B) with improved chemical stability in phosphate buffer (pH 7.4) and cytotoxicity against colorectal adenocarcinoma (Caco-2) cells in comparison with curcumin [1]. It also demonstrated superior anti-HepG2 hepatocellular carcinoma activities in the in vitro and in vivo models [2, 3]. Encapsulation of CDD in various types of nanoparticles increased cellular uptake and cytotoxicity of CDD against several cancer cell lines [4, 5, 6]. Furthermore, CDD at doses of 25 and 200 mg/kg exhibited analgesic activities and anti-inflammatory effects in mouse models [7]. Pharmacokinetic studies of CDD in rats showed that CDD was rapidly converted to curcumin and increased plasma concentrations of curcumin after intravenous administration [8, 9]. The in vitro plasma metabolism study indicates that plasma carboxylesterase is an enzyme responsible for the hydrolysis of CDD in rats [10]. Therefore, CDD has the potential to be further developed as a prodrug of curcumin for various therapeutic applications.

Quality control of drug substances is one of the key factors in the development of a new molecular entity for pre-clinical and clinical studies. An analytical method for quality control of active pharmaceutical ingredients (APIs) and drug products should be a validated stability-indicating method (SIM) [11, 12]. The SIM is usually a chromatography-based method that can quantify target analytes without interferences from impurities generated during the manufacturing process and storage. The development of SIM requires forced-degradation samples that can be prepared by exposing APIs or drug products to different stress conditions, including acid, base, moisture, heat, light, and oxidizing agents [12]. The SIM can be achieved by assessment of the ability of the method to efficiently separate target analytes from its degradation products using the forced degradation samples.

To date, a number of liquid chromatography-based methods for CDD analysis have been reported. The first reported method is the HPLC-UV method with an application in a chemical kinetic study for curcuminoid prodrugs [1]. The method is time-consuming and lacks specificity, which limits its application for the quality control of CDD raw materials. Other HPLC-UV methods were developed to determine CDD and

* Corresponding author.
E-mail address: pornchai.r@chula.ac.th (P. Rojsithisak).

https://doi.org/10.1016/j.heliyon.2020.e04561
Received 20 May 2020; Received in revised form 5 July 2020; Accepted 22 July 2020
2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
curcumin in plasma [10] or in Caco-2 permeates [2]. However, the methods have not yet been validated and proved to be SIM. Recently, we reported the validated LC-MS/MS method for the pharmacokinetic study of CDD in rats [8]. Although the LC-MS/MS is a powerful tool for analysis of target analytes due to its high sensitivity and specificity, the method is a high-cost technique and may be unnecessary for the quantitative analysis of target analytes in APIs. Up to date, the validated SIM for the quantitative determination of CDD raw materials based on liquid chromatography coupled with UV-vis detection for the analysis of CDD has not been reported.

In the present study, we developed and validated a UPLC method for the quantitative determination of CDD content in raw materials. Forced degradation studies of CDD under different stress conditions, including acid, base, moisture, heat, light, and oxidation, were conducted to facilitate the development of the SIM that could analyze CDD with acceptable specificity. The method was found to be efficient for the separation of CDD from its degradation products and successfully validated according to the ICH Q2(R1) guideline [13] in terms of specificity, accuracy, precision, and sensitivity.

2. Experimental

2.1. Materials and reagents

CDD, monoethylsuccinyl curcumin (MEC, Figure 1C), and curcumin (purity >98%, by HPLC) were synthesized using the previously published methods [1,10] and used as the reference standards in the validation and assay. One pilot batch of CDD raw material was prepared in our laboratory [2] while a manufacturing batch was obtained from Chengdu BK Biotech Co., Ltd. (Sichuan, China). Reagent-grade glacial acetic acid was obtained from Scharlab (Barcelona, Spain). HPLC-grade acetonitrile was procured from Thomas Baker (Mumbai, India). Reagent-grade dimethyl sulfoxide (DMSO) was purchased from Carlo Erba (Val de Reuil, France). High purity water was prepared in-house using UHQ Water System (Milli-Q, USA). Quinine monohydrochloride dihydrate USP standard (Lot no. R07150, purity 100%) was purchased from USP.

2.2. Instrumentation

The Waters ACQUITY UPLC® H-Class system (Waters Corporation, Milford, MA, USA) comprised of quaternary pump, column oven, autosampler, and photodiode array detector was used for method development, forced degradation studies, and method validation. The Empower 3 software was used for controlling instrument operation and processing data. Chromatographic separation was achieved on an ACQUITY UPLC® BEH C18 1.7 μm, 2.1 × 50 mm column (Waters Chromatography Ireland Limited, Dublin, Ireland). The mobile phase consisting of 2% v/v acetic acid in water (A) and acetonitrile (B) was delivered at a flow rate of 0.3 mL/min. The gradient elution program was optimized as follows: initial A-B of 55:45 at 0.0 min; linear-gradient A-B of 20:80 from 0.0–2.7 min; isocratic A-B of 20:80 from 2.7–4.5 min; linear-gradient A-B of 55:45 from 4.5–5.0 min; isocratic A-B of 55:45 from 5.0–7.0 min. The column oven temperature and detection wavelength were set at 33 °C and 400 nm, respectively. The injection volume was 2 μL.

2.3. Preparation of standard and system suitability solutions

Standard stock solutions of CDD, curcumin, and MEC (100 μg/mL) were separately prepared by dissolving 5 mg of each compound with DMSO in 50-mL volumetric flasks. A 5 mL of the stock standard solution of CDD was transferred to another 50-mL volumetric flask and diluted to volume with a diluent (20:80 of 2% v/v acetic acid in water:acetonitrile) to obtain a working standard solution of CDD at the concentration of 10 μg/mL. Standard solutions of curcumin and MEC at the concentration of 10 μg/mL were prepared similarly to the working standard solution of CDD. Then, the standard solutions were filtered through 0.45 μm nylon membrane filters before analysis.

A system suitability solution was prepared by diluting the standard stock solutions of CDD, curcumin, and MEC (100 μg/mL) with the diluent to obtain a solution containing 10 μg/mL of each compound. The system suitability solution was filtered through a 0.45 μm nylon membrane filter before analysis.

2.4. Forced degradation studies

Forced degradation studies of CDD under six stress conditions were performed as recommended by the ICH Q1A(R2) guideline [11]. The samples were prepared at the nominal concentration of 10 μg/mL and filtered through a 0.45 μm nylon membrane filter before analysis.

2.4.1. Procedure for acid hydrolysis

A 5 mg of CDD was added into a 15-mL glass-stopper test tube followed by the addition of 200 μL of 0.1 N HCl. The mixture was vortexed until homogeneously dispersed. The sample was kept at 80 °C for 3 h. Then, 200 μL of 0.1 N NaOH was added to neutralize the residual acid. After that, the sample was further dissolved with 10 mL of DMSO. The resulting solution was transferred to a 50-mL volumetric flask followed by diluting to volume with DMSO. Subsequently, 1 mL of this solution

![Figure 1. Chemical structures of (A) curcumin diethyl disuccinate, CDD (B) curcumin, and (C) monoethylsuccinyl curcumin, MEC.](image-url)
was pipetted into a 10-mL volumetric flask and diluted to volume with the diluent.

2.4.2. Procedure for basic hydrolysis

A 5 mg of CDD was dispersed in 200 μL of 0.1 N NaOH in a 15-mL glass-stopper test tube. The mixture was vortexed until homogeneously dispersed. The sample was incubated at 80 °C for 3 h. Then, 200 μL of 0.1 N HCl was added to neutralize the residual hydroxide. After that, the sample was further dissolved with 10 mL of DMSO. The resulting solution was transferred to a 50-mL of volumetric flask and made up to the volume with DMSO. Subsequently, 1 mL of this solution was pipetted into a 10-mL volumetric flask and diluted to volume with the diluent.

2.4.3. Procedure for moisture hydrolysis

A 5 mg of CDD was dispersed in 200 μL of water in a 15-mL glass-stopper test tube. The mixture was vortexed until homogeneously dispersed. The sample was heated at 80 °C for 3 h. After that, the remaining sample was dissolved with 10 mL of DMSO. The resulting solution was transferred to a 50-mL volumetric flask followed by diluting to volume with DMSO. Afterward, 1 mL of this solution was transferred into a 10-mL volumetric flask and diluted to volume with the diluent.

2.4.4. Procedure for oxidative degradation

A 5 mg of CDD was mixed with 200 μL of 3% H2O2 in a 15-mL glass-stopper test tube and incubated at 80 °C. After 3 h, the residual sample was dissolved with 10 mL of DMSO and subsequently transferred to a 50-mL of volumetric flask. The transferred solution was diluted to volume with DMSO. Then, 1 mL of the solution was pipetted into a 10-mL volumetric flask and diluted to volume with the diluent.

2.4.5. Procedure for thermal degradation

A 5 mg of CDD was heated at 80 °C in a 15-mL glass-stopper test tube. After that, the sample was dissolved with 10 mL of DMSO, transferred to a 50-mL volumetric flask, and adjusted to volume with DMSO. Then, 1 mL of the solution was transferred to a 10-mL volumetric flask and diluted to volume with the diluent.

2.4.6. Procedure for photolysis

The photostability of CDD was investigated in both solid substance and solution according to the ICH Q1B guideline [14]. A 2 %w/v aqueous solution of quinine monohydrochloride dihydrate in a 1-cm quartz cell was used as light intensity indicator. The quinine solution was placed beside the test sample during the study. The experiment is appropriately performed to obtain a nominal concentration of 200-Watt h/m2. For the photostability of CDD as solution, the quinine solution was placed in a 1-cm quartz cell and diluted to volume with the diluent.

2.4.7. Procedure for photolysis

The photostability of CDD as solution was determined by the spiked standard method and expressed as %recovery calculated using the following equation:

\[
%\text{recovery} = \frac{\text{Amount found (µg/mL) - Amount added (µg/mL)}}{\text{Amount added (µg/mL)}} \times 100
\]
2.5.6. Precision

Precision of the analytical procedure was evaluated by determining repeatability (intra-day precision) and intermediate precision of the method. Repeatability was assessed by triplicate injections of three replicates of the CDD standard solutions at 8, 10, and 12 μg/mL prepared as described in section 2.5.5. For intermediate precision, three replicates of the CDD standard solutions at 8, 10, and 12 μg/mL were assayed in triplicate on two different days by two different analysts.

2.5.7. Robustness

Robustness of the developed method was investigated under small variations in method parameters, including the detection wavelength and column temperature. Suitability of system including retention time and peak response of CDD was observed when method parameters were varied from regular method condition. Furthermore, the sample solution stability was also observed in comparison with the freshly prepared standard solution.

Table 1. System suitability parameters (n = 5).

| Injection no. | Retention time (min) | Peak response | USP Tailing factor | USP plate count |
|---------------|----------------------|---------------|--------------------|-----------------|
| 1             | 3.721                | 340560        | 1.11               | 109777          |
| 2             | 3.712                | 339777        | 1.11               | 108260          |
| 3             | 3.709                | 340580        | 1.10               | 106986          |
| 4             | 3.707                | 340448        | 1.08               | 102171          |
| 5             | 3.710                | 339689        | 1.07               | 101671          |
| Mean          | 3.712                | 340251        | 1.09               | 105773          |
| %CV           | 0.15                 | 0.12          |                    |                 |

Figure 2. (A) Overlaid chromatograms of diluent, curcumin standard solution, CDD standard solution, and MEC standard solution. (B) A chromatogram of the mixture solution of curcumin, MEC and CDD.
2.5.8. Method application for quality control of CDD raw materials

The methodology was applied in the quantitative analysis of 2 batches of CDD raw materials. The working standard and system suitability solutions were prepared as described in section 2.3. CDD samples from different batches were separately prepared at the final concentration of 10 μg/mL in the diluent. Then, these solutions were filtered through a 0.45 μm nylon membrane filter prior to analysis. The percentages of weight (%w/w) of CDD in raw materials were determined by comparing the peak responses of the CDD samples with that of the working standard solution.

3. Results and discussion

3.1. Method development

Two potential impurities in CDD raw materials are curcumin and MEC. Curcumin is a starting material for CDD synthesis, while MEC is an intermediate occurred during an esterification reaction. In addition, both curcumin and MEC can be generated via the ester hydrolysis of CDD during the storage of CDD raw materials. Therefore, the analytical method developed for the quantitative determination of CDD in raw materials required efficient separation of CDD from curcumin and MEC. The chromatographic separation of CDD from its degradation products was achieved with the gradient elution program varying the ratio of 2% v/v acetic acid in water (A) and acetonitrile (B) at the flow rate of 0.3 mL/min. Initially, acetonitrile was ramped up from 45% to 80% in a linear fashion for 2.7 min (from 0-2.7 min) to ensure that the analytes can be separated on the column. The UPLC chromatograms of the diluent, the curcumin standard solution, the MEC standard solution, the CDD standard solution, and the system suitability solution containing curcumin, MEC, and CDD are shown in Figure 2. Curcumin was eluted at 1.6 min, corresponding to the elution of curcumin at about 66% acetonitrile. Subsequently, acetonitrile was maintained at 80% for 1.8 min (from 2.7-4.5 min) for elution of CDD and other impurities. At 80% acetonitrile, MEC and CDD were eluted at 2.8 and 3.6 min, respectively. Finally, acetonitrile was decreased from 80% to 45% in 0.5 min and maintained for another 2 min prior to subsequent injection. The use of acetic acid at 2 %v/v in water is adequately acted as a mobile phase additive for suppressing tautomerization of curcumin. The lower amount of acetic acid is insufficient to make this suppression while the higher amount of acetic acid is not appropriate due to its unpleasant odor which is not environment-friendly during instrument operation. Formic acid is more

Figure 3. (A) Overlaid chromatograms of forced degradation samples of CDD under various conditions. (B) The zoomed overlaid chromatograms of forced degradation samples of CDD.
Table 2. Peak purity values of curcumin diethyl disuccinate under various stress conditions.

| Treatment                                           | Purity angle | Purity Threshold | Peak purity* |
|-----------------------------------------------------|--------------|------------------|--------------|
| Control                                             | 0.437        | 3.156            | Passed       |
| Acid Hydrolysis (0.1 N HCl) at 80 °C for 3 h.       | 0.536        | 3.782            | Passed       |
| Basic Hydrolysis (0.1 N NaOH) at 80 °C for 3 h.     | 1.874        | 12.131           | Passed       |
| Oxidative stress (3% H2O2) at 80 °C 3 h.            | 0.655        | 4.296            | Passed       |
| Temperature degradation at 80 °C for 3 h.           | 0.575        | 4.060            | Passed       |
| Moisture hydrolysis at 80 °C for 3 h.               | 0.584        | 4.149            | Passed       |
| Photolysis in solid state, 1.2 million lux h.       | 0.546        | 3.522            | Passed       |
| Photolysis in solution, 1.2 million lux h.          | 0.651        | 3.693            | Passed       |

* The peak purity value is valid when the purity threshold value is greater than the purity angle value.

3.2. System suitability

Suitability of system was verified to ensure the validity of chromatographic condition prior to performing experiments. The resolutions between curcumin and MEC, and between MEC and CDD were 14.7 and 14.1, respectively. The average USP tailing factor of CDD was 1.09. These results indicate that the method provides sufficient chromatographic separation with symmetrical peak shape. Deviations of the peak area and retention time in terms of %CV were used to demonstrate the system reproducibility. The %CV values of peak area and retention time

P. Ratnatilaka Na Bhuket et al. Heliyon 6 (2020) e04561

Figure 4. Linearity of the method. (A) Calibration curve of CDD and (B) Residual plot of linearity.
of CDD were found to be 0.12 and 0.15 %, respectively. The USP plate count was greater than 20,000. The system suitability results shown in Figure 2 and summarized in Table 1 suggest the suitability of the chromatographic system for CDD analysis.

3.3. Specificity and forced degradation studies

Specificity is the ability of the analytical method to discriminate an analyte from matrix components, impurities, and degradation products. As shown in Figure 2, there is no interference observed at the retention time of CDD. The chromatograms show no coelution peaks of the known degradation products (MEC and curcumin) at the retention time of CDD. According to Figure 3, the forced degradation results showed that CDD degraded under the stress conditions with different extents. CDD was stable under the photodegradation in the powder form but degraded into several degradation products under other stress conditions. Although the chromatograms of the forced degradation samples had a small peak of the unknown degradation product at 3.5 min prior to the CDD peak, the resolution between such peak and CDD is greater than 2, indicating the sufficient separation. It is noteworthy that each degradation product was observed with the small chromatographic peak area although CDD underwent substantial degradation, indicating the poor mass balance in the forced degradation studies of CDD. In addition, curcumin as the expected impurity was not observed on the chromatograms. It is evident that curcumin degrades to other degradation products such as ferulic acid, feruloyl methane, vanillin, spiroepoxides, and bicyclopentadiones, which do not contain chromophores that absorb the wavelength used in this method [15, 16]. MEC presented as a small chromatographic peak on the chromatograms under the stress conditions possibly due to its rapid degradation into curcumin and other degradation products similar to the degradation pathways of curcumin. The occurrence of the degradation products with the absence of chromophores that can absorb the wavelengths used in this method possibly leads to the poor mass balance in the forced degradation studies of CDD. The purity indices determined using the Empower 3 software for the CDD peak on the chromatograms of all stress test samples were found to be higher than the purity angle as shown in Table 2. The peak purity analysis results indicated that the CDD peak had no co-eluting compounds. The overall forced degradation results indicated that the method had sufficient specificity and was subsequently validated as the SIM for the quantitative determination of CDD in raw materials.

3.4. Linearity and range

System linearity was determined in the range of 8–12 μg/mL of the CDD standard solutions in triplicate. A plot between the concentrations versus the peak responses of CDD, linear regression equation and coefficient of determination ($r^2$) are shown in Figure 4A. Linear regression analysis showed that the method was linear over the concentration range of 8–12 μg/mL. The residual plot showed that residuals of response were

| Target Level | Amount added (μg/mL) | Amount found (μg/mL) | %Recovery |
|--------------|----------------------|----------------------|-----------|
| 80%          | 8.17                 | 8.03                 | 98.4      |
|              | 8.17                 | 8.03                 | 98.3      |
|              | 8.17                 | 8.07                 | 98.8      |
| 100%         | 10.25                | 10.17                | 99.2      |
|              | 10.25                | 10.32                | 100.8     |
|              | 10.25                | 10.22                | 99.8      |
| 120%         | 12.11                | 12.12                | 100.1     |
|              | 12.11                | 12.14                | 100.3     |
|              | 12.11                | 12.11                | 100.0     |

Table 3. Range of the method.

| Level (%) | Amount added (μg/mL) | Amount found (μg/mL) |
|-----------|----------------------|----------------------|
| 80        | 8.07                 | 7.99                 |
| 90        | 9.08                 | 8.98                 |
| 100       | 10.09                | 10.02                |
| 110       | 11.10                | 11.00                |
| 120       | 12.11                | 12.08                |
| Slope/intercept | 1.0097/0.1732 |
| Coefficient of determination ($r^2$) | 0.9998 |

Table 4. Limit of detection (LOD) and limit of quantitation (LOQ) (n = 5).

| Injection no. | LOD Peak response | Sample no. | LOQ Added (μg/mL) | Found (μg/mL) | %Recovery | S/N |
|---------------|-------------------|------------|-------------------|---------------|-----------|-----|
| 1             | 1760              | 12         | 1                 | 0.0752        | 0.0724    | 96.3| 14  |
| 2             | 1580              | 10         | 2                 | 0.0752        | 0.0708    | 94.1| 14  |
| 3             | 1548              | 11         | 3                 | 0.0752        | 0.0752    | 100.0| 14  |
| 4             | 1574              | 11         | 4                 | 0.0752        | 0.0720    | 95.7| 14  |
| 5             | 1583              | 11         | 5                 | 0.0752        | 0.0692    | 92.0| 14  |
| Mean          | 1609              | 11         |                  | 0.0719        | 95.6      | 14  |
| %CV           |                   |            |                  |               | 3.1%      |     |

Table 5. Accuracy of UPLC analysis of CDD (n = 3).

| Target Level | Amount added (μg/mL) | Amount found (μg/mL) | %Recovery |
|--------------|----------------------|----------------------|-----------|
| 80%          | 8.17                 | 8.03                 | 98.4      |
|              | 8.17                 | 8.03                 | 98.3      |
|              | 8.17                 | 8.07                 | 98.8      |
| 100%         | 10.25                | 10.17                | 99.2      |
|              | 10.25                | 10.32                | 100.8     |
|              | 10.25                | 10.22                | 99.8      |
| 120%         | 12.11                | 12.12                | 100.1     |
|              | 12.11                | 12.14                | 100.3     |
|              | 12.11                | 12.11                | 100.0     |
independent on the established concentrations (Figure 4B). Range of the method was also evaluated over the CDD concentration range of 8–12 μg/mL. The amounts of CDD added and found and regression analysis for the range were summarized in Table 3.

3.5. LOD and LOQ

The LOD and LOQ for CDD analysis were experimentally determined and the results showed that the concentration for LOD was 0.050 μg/mL (%CV = 5.3) with the S/N of 11, while the concentration for LOQ was 0.075 μg/mL with the S/N of 14. The %recovery was within 92–100% with the %CV of 3.1. The LOD and LOQ results summarized in Table 4 indicated sufficient sensitivity for the assay of CDD in raw materials.

3.6. Accuracy and precision

Accuracy of the analytical method of the assay of CDD was expressed as %recovery. The %recovery values range from 98.3–100.8%. The %recovery values at each concentration level are presented in Table 5. Precision of the analytical method is expressed as %CV. The %CV for repeatability was 0.9%. The intermediate precision was demonstrated by analysis of CDD in the different day by different analyst. The %CV for intermediate precision was 0.8%. The results of repeatability and intermediate precision are summarized in Table 6.

3.7. Robustness

The system suitability solution was prepared and injected in six replicates with variations of detection wavelength and column temperature to assess robustness of the method. The retention times of CDD were relatively similar when the chromatographic system was carried out using different detection wavelengths and column temperatures. In addition, the small variations of detection wavelength and column had no impact on the %CV of retention time and peak response (%CV < 2%). The results of robustness are summarized in Table 7. Furthermore, stability of the CDD standard solution at 10 μg/mL was also evaluated to ensure the bench top shelf-life (25 ± 5 °C) of the solution during the experiment for 6 h as shown in Table 8. The results implied that the

### Table 6. Repeatability and intermediate precision of CDD analysis (n = 3).

| Type of precision | %Recovery of CDD solutions at target levels |
|-------------------|-------------------------------------------|
|                   | 80% | 100% | 120% |
| **Repeatability** |
| 1st replicate     | 98.4| 99.2 | 100.1|
| 2nd replicate     | 98.3| 100.8| 100.3|
| 3rd replicate     | 98.8| 99.8 | 100.0|
| **Mean (n = 3)**  | 98.5| 99.9 | 100.1|
| **%CV**           | 0.2 | 0.8  | 0.1  |
| **Intermediate precision** |
| **Analyst 1**     |
| 1st replicate     | 98.4| 99.2 | 100.1|
| 2nd replicate     | 98.3| 100.8| 100.3|
| 3rd replicate     | 98.8| 99.8 | 100.0|
| **Analyst 2**     |
| 1st replicate     | 98.2| 98.6 | 98.2 |
| 2nd replicate     | 98.1| 98.7 | 98.5 |
| 3rd replicate     | 99.5| 99.6 | 99.1 |
| **Mean (n = 18)** | 99.1|      |      |
| **%CV**           | 0.8 |      |      |

### Table 7. Robustness of the developed method (n = 5).

| Parameters                | Modification          | Retention time (min) | Peak response |
|---------------------------|-----------------------|----------------------|---------------|
|                           |                       | Mean (min) | %CV | Mean | %CV |
| Detection wavelength (nm) | 400                   | 3.549      | 0.1 | 332237 | 0.4 |
|                           | 398                   | 3.555      | 0.1 | 332299 | 0.5 |
|                           | 402                   | 3.553      | 0.0 | 329458 | 0.5 |
| Column temperature (°C)   | 33                    | 3.549      | 0.1 | 332237 | 0.4 |
|                           | 31                    | 3.570      | 0.2 | 334159 | 0.2 |
|                           | 35                    | 3.529      | 0.1 | 332470 | 0.4 |

### Table 8. Stability of the CDD standard solution at 10 μg/mL (n = 1).

| Time (h) | % remaining |
|----------|-------------|
| 0        | 100.0       |
| 4        | 98.0        |
| 6        | 99.2        |

### Table 9. The percentage amount (%w/w) of two batches of CDD raw materials.

| Lot no. | Batch size | Mfg. date | %w/w |
|---------|------------|-----------|------|
| B#201611110 | 85 G       | 10-11-16  | 98.4 |
| B#20180717 | 1 KG       | 17-07-18  | 96.9 |
chromatographic condition and sample preparation for CDD are practically robust.

3.8. Method application for quality control of CDD raw materials

The validated method was applied in quality control of CDD raw materials. Two batches of CDD were analyzed. The CDD raw material from the pilot scale (lot no. B#20161110) has higher CDD purity than the batch from the 1-kg manufacturing batch (lot no. B#20180717). These results suggest that the large-scale CDD synthesis procedure may need additional optimization to attain CDD raw materials with higher purity. The assay results reporting as on dried basis are summarized in Table 9.

4. Conclusion

A fast, specific, precise, accurate, and robust stability-indicating reversed-phase UPLC method for CDD analysis was developed. Forced degradation studies showed that CDD was degraded under acid hydrolysis, oxidation, moisture hydrolysis and solution-state photolysis conditions. The developed method is capable to efficiently separate CDD from its degradation products. The proposed method here can be employed in the quality control of CDD raw materials.

Declarations

Author contribution statement

P. Rojsitthisak, P. Ratnatilaka Na Bhuket and W. Wichitnithad: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.
O. Sutanon: Performed the experiments; Analyzed and interpreted the data.

Funding statement

This work is supported by Chulalongkorn University (Grant No. CU_GR_62_97_33_06).

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] W. Wichitnithad, U. Nimmannt, S. Wacharasindhu, P. Rojsitthisak, Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment, Molecules 16 (2) (2011) 1888–1900.
[2] C. Muangnoi, P. Ratnatilaka Na Bhuket, P. Jitavee, W. Supasaeng, L. Paraoon, S. Patumraj, P. Rojsitthisak, Curcumin diethyl disuccinate, a prodrug of curcumin, enhances anti-proliferative effect of curcumin against HepG2 cells via apoptosis induction, Sci. Rep. 9 (1) (2019) 11718.
[3] C. Muangnoi, P. Ratnatilaka Na Bhuket, P. Jitavee, W. Wichitnithad, O. Srikun, C. Nerungsi, S. Patumraj, P. Rojsitthisak, Scale-up synthesis and in vivo anti-tumor activity of curcumin diethyl disuccinate, an enter prodrug of curcumin, in HepG2 xenograft mice, Pharmacaceutics 11 (8) (2019) 373.
[4] S. Bhanthu, C. Muangnoi, P. Rojsitthisak, P. Rojsitthisak, Curcumin diethyl disuccinate encapsulated in chitosan/alginicate nanoparticles for improvement of its in vitro cytotoxicity against MDA-MB-231 human breast cancer cells, Pharmazie 71 (12) (2016) 691–700.
[5] S. Bhanthu, P. Rojsitthisak, P. Rojsitthisak, Effects of preparation parameters on the characteristics of chitosan-alginicate nanoparticles containing curcumin diethyl disuccinate, J. Drug Deliv. Sci. Technol. 28 (2015) 64–72.
[6] F.N. Sorasitthiyanukarn, C. Muangnoi, W. Thaweeset, P. Rojsitthisak, P. Rojsitthisak, Enhanced cytotoxic, antioxidant and anti-inflammatory activities of curcumin diethyl disuccinate using chitosan-tripolyphosphate nanoparticles, J. Drug Deliv. Sci. Technol. 53 (2019) 101118.
[7] J. Wongrisiakul, W. Wichitnithad, P. Rojsitthisak, P. Towiawat, Antinociceptive effects of curcumin diethyl disuccinate in animal models, J. Health Res. 24 (4) (2010) 175–180.
[8] P. Ratnatilaka Na Bhuket, N. Niwattisaiwong, P. Limpikirati, P. Khemawoot, P. Towiawat, B. Onqipipattanakul, P. Rojsitthisak, Simultaneous determination of curcumin diethyl disuccinate and its active metabolite curcumin in rat plasma by LC-MS/MS: application of esterase inhibitors in the stabilization of an ester-containing prodrug, J. Chromatogr. B 1033–1034 (2016) 301–310.
[9] K. Bangphumi, C. Kittiviriyakul, P. Towiawat, P. Rojsitthisak, P. Khemawoot, Pharmacokinetics of curcumin diethyl disuccinate, a prodrug of curcumin, in Wistar rats, Eur. J. Pharmaceut. Biomed. Anal. 15 (12) (1997) 1867–1876.
[10] P. Ratnatilaka Na Bhuket, P. Jitavee, B. Onqipipattanakul, P. Rojsitthisak, Interspecies differences in stability kinetics and plasma esterases involved in hydrolytic activation of curcumin diethyl disuccinate, a prodrug of curcumin, in HepG2-C-2-Luc cells, J. Drug Deliv. Sci. Technol. 53 (2019) 101118.
[11] International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline Q1A: Stability Testing of New Drug Substances and Products, 2003.
[12] A.F. Aubry, P. Tattersall, J. Ruan, Development of stability indicating methods, in: K. Huynh-Ba (Ed.), Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies, and Best Practices, Springer, New York, NY, 2009, pp. 139–161.
[13] International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology, 2005.
[14] International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline Q1B: Stability Testing: Photostability Testing of New Drug Substances and Products, 1996.
[15] Y.J. Wang, M.H. Pan, A.L. Cheng, L.I. Lin, Y.S. Ho, C.Y. Hsieh, J.K. Lin, Stability of curcumin in buffer solutions and characterization of its degradation products, J. Pharmaceut. Biomed. Anal. 15 (12) (1997) 1867–1876.
[16] O.N. Gordon, P.B. Lais, H.O. Sinnitt, C. Schneider, Unraveling curcumin degradation: autoxidation proceeds through spiroepoxide and vinyl ether intermediates en route to the main bicyclopentadione, J. Biol. Chem. 290 (8) (2015) 4817–4826.